low - Stroke and pulmonary embolism procedures are medically urgent and non-discretionary. Hospital capital equipment purchases show modest cyclicality during severe recessions when hospital systems defer investments, but disposable device volumes remain stable. Medicare and commercial insurance reimbursement provides revenue stability independent of GDP fluctuations. International growth may show sensitivity to healthcare spending cycles in emerging markets.

Rising rates create modest headwind through higher hospital cost of capital for equipment purchases and potential pressure on valuation multiples for high-growth medtech stocks trading at 10x sales. Company maintains minimal debt (0.16 D/E) so direct financing cost impact is negligible. Rate environment affects M&A capacity and competitive dynamics if larger medtech acquirers face higher financing costs.

growth - Investors focus on 12.9% revenue growth, large addressable market expansion in stroke and peripheral vascular intervention, and potential for margin expansion as company scales. Stock trades at 10x sales reflecting expectations for sustained double-digit growth and eventual operating margin expansion toward 20%+ medtech peer levels. Recent 25.7% one-year return and 34.7% six-month return indicate momentum investor participation. Negative EPS growth of -84.6% reflects investment phase prioritizing market share over profitability.